Taigen Biopharmaceuticals Holdings Ltd (4157) — Cash Flow Quality Index
Taigen Biopharmaceuticals Holdings Ltd (4157) has a Cash Flow Quality Index of 0.23x as of December 2025. Operating cash flow of NT$46.51 Million is below net income of NT$204.72 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore 4157 cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Taigen Biopharmaceuticals Holdings Ltd Cash Flow Quality Index (2011–2025)
Historical Cash Flow Quality Index for Taigen Biopharmaceuticals Holdings Ltd across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Taigen Biopharmaceuticals Holdings Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Taigen Biopharmaceuticals Holdings Ltd (2011–2025)
Year-by-year earnings quality comparison for Taigen Biopharmaceuticals Holdings Ltd. For live market cap and the full company financial profile, see Taigen Biopharmaceuticals Holdings Ltd market cap and net worth.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.46x | NT$20.93 Million | NT$45.18 Million | ▲ +205.4% |
| 2023 | 0.15x | NT$20.74 Million | NT$136.73 Million | ▼ -78.9% |
| 2021 | 0.72x | NT$629.07 Million | NT$875.99 Million | ▲ +300.8% |
| 2017 | -0.36x | NT$-266.93 Million | NT$746.38 Million | ▲ +96.0% |
| 2011 | -8.85x | NT$-379.23 Million | NT$42.84 Million | — |